Definition

A preparation of autologous T lymphocytes that are genetically engineered to express a fourth-generation chimeric antigen receptor (4SCAR) targeting the two tumor-associated antigens (TAAs) disialoganglioside (GD2) and prostate-specific membrane antigen (PSMA), with potential immunostimulating and antineoplastic activities. Upon administration, the autologous anti-GD2/anti-PSMA 4SCAR-expressing bispecific T cells are directed to and induce selective toxicity in GD2- and PSMA-expressing tumor cells. GD2 is overexpressed on the surface of neuroblastoma (NB) cells and by other neuroectoderm-derived neoplasms, while it is minimally expressed on normal cells. PSMA, a type II transmembrane protein, is expressed on the membrane of prostatic epithelial cells and overexpressed on prostate tumor cells as well as a variety of other solid tumors, including brain tumor, NB and some lymphoma tumor tissues.